Universitaire Ziekenhuizen KU Leuven

30 marketed · 5 in Phase 3

Quick facts

Marketed products

Phase 3 pipeline

Phase 2 pipeline

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Universitaire Ziekenhuizen KU Leuven

What are Universitaire Ziekenhuizen KU Leuven's marketed drugs?

Top marketed products include Alginate, Apixaban single dose, Apixaban steady-state, Buspirone Hydrochloride 10 MG, Citalopram HCl, Corticotropin-release hormone.

What is Universitaire Ziekenhuizen KU Leuven's pipeline?

Universitaire Ziekenhuizen KU Leuven has 5 drugs in Phase 3, 4 in Phase 2, 2 in Phase 1. Late-stage candidates include Androgen receptor targeted therapy, artificial lacrimal tears, Placebo: Oil, Rikkunshi-to.

Related